1. Home
  2. ASC vs ACRS Comparison

ASC vs ACRS Comparison

Compare ASC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardmore Shipping Corporation

ASC

Ardmore Shipping Corporation

HOLD

Current Price

$15.78

Market Cap

571.6M

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.32

Market Cap

608.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASC
ACRS
Founded
2010
2012
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
571.6M
608.9M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
ASC
ACRS
Price
$15.78
$5.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$17.00
$10.20
AVG Volume (30 Days)
681.6K
2.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
1.74%
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
N/A
$1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4.24
P/E Ratio
$16.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.90
$1.46
52 Week High
$20.03
$5.85

Technical Indicators

Market Signals
Indicator
ASC
ACRS
Relative Strength Index (RSI) 47.28 55.46
Support Level $14.91 $4.13
Resistance Level $15.98 $5.85
Average True Range (ATR) 0.77 0.31
MACD 0.13 -0.01
Stochastic Oscillator 66.03 50.00

Price Performance

Historical Comparison
ASC
ACRS

About ASC Ardmore Shipping Corporation

Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: